- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04035278
A Phase 1 Safety Study of Dengusiil in Healthy Adults
December 29, 2023 updated by: Serum Institute of India Pvt. Ltd.
A Phase 1, Double Blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Dengusiil in Healthy Adults
This is a Phase 1 study to assess safety and tolerability of a single subcutaneous dose of Dengusiil in healthy adults of 18 to 45 years of age.
In this study, immune response to Dengusiil will also be assessed over a period of 6 months and vaccine viremia will also be assessed over a period of 12 days after administration of vaccine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- CMAX Clinical Research Pty Ltd
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 43 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy adults aged 18-45, men, or women.
- Seronegative for Dengue NS1 and IgM at screening indicating no current dengue infection
- Seronegative for dengue IgG at screening
- Participants who are willing to comply with the requirements of the study protocol and attend scheduled visits.
- Participants who give written informed consent approved by the Human Research Ethics Committee (HREC) governing the site.
- Participants must have the laboratory parameters within normal range.
- Participants with Body Mass Index (BMI) between 18 to 30 (both inclusive)
- Satisfactory baseline medical assessment as assessed by physical examination and normal laboratory values or minor variations those are acceptable for study entry.
Participants should agree to not:
- donate blood for the purpose of blood transfusion
- donate an organ for the purpose of transplantation
- to share needles with other people
- allow their blood to come in contact with another person's mucous membranes for 84 days post-vaccination.
Exclusion Criteria:
- Previous dengue vaccination.
- Presence of acute infection in the preceding 14 days or presence of a temperature ≥ 38.0°C, or acute symptoms of infection greater than of "mild" severity on the scheduled date of first dosing
- Evidence of any other significant active haematological disease, or having donated > 450 mL of blood within the past three months.
- Evidence or history of substance abuse including alcohol or previous substance abuse within the last year.
- Participation or planned participation in a study involving the administration of an investigational compound within the past one month or during this study period.
- Planned administration of any vaccine not foreseen by the study protocol 4 weeks before and after dosing.
- History of allergic disease, allergic reactions or known hypersensitivity to any component of the study vaccines.
- Confirmed or suspected immunosuppressive or immune-deficient condition.
- A family history of congenital or hereditary immunodeficiency.
- Chronic administration (defined as more than 14 days) of immune-suppressants or other immune-modifying agents within six months prior to administration of study vaccine. (For corticosteroids, this means prednisone, or equivalent, ≥ 0.5 mg/kg/day; topical or inhalable steroids are allowed.)
- Laboratory confirmed infection with either hepatitis B virus (HBs Ag positive), hepatitis C virus (anti-HCV positive), or human immunodeficiency virus (HIV) at screening.
- Known bleeding disorders.
- Administration of immunoglobulins and/or any blood products within the three months preceding the administration of study vaccines or planned administration during the study period.
- Women who are pregnant, breast-feeding, or considering becoming pregnant.
- Any other condition, which in the opinion of the investigator, might interfere with the study objectives, jeopardize the safety or rights of the participant or making it unlikely the participant could complete the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo is supplied as a vial of lyophilized powder containing all the components of the vaccine except dengue virus serotypes (DENV1, 2, 3 and 4) to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted product is injected as a single 0.5 mL subcutaneous (SC) dose.
Other Names:
|
Experimental: Dengusiil
|
Dengusiil is provided as lyophilized powder to be reconstituted with 0.5 mL sterile water for injection (sWFI).The reconstituted vaccine is injected as a single 0.5 mL subcutaneous (SC) dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Solicited local and systemic reactions
Time Frame: 21 days
|
21 days
|
Occurrence, severity, and relatedness to vaccination of unsolicited adverse events
Time Frame: 21 days
|
21 days
|
Occurrence, severity, and relatedness to vaccination of serious adverse events
Time Frame: 180 days
|
180 days
|
Proportion of participants with clinically significant abnormal safety laboratory (hematology and chemistry parameters) findings
Time Frame: 8 days
|
8 days
|
Proportion of participants with clinically significant physical examination and vital signs findings
Time Frame: 180 days
|
180 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of participants with seroconversion for DENV-1 to 4 virus neutralization antibodies (PRNT50) titer
Time Frame: 84 days
|
84 days
|
The percentage of participants seropositive for DENV-1 to 4 virus neutralizing antibodies
Time Frame: 84 days
|
84 days
|
The percentage of participants seropositive for DENV-1 to 4 virus neutralizing antibodies
Time Frame: 180 days
|
180 days
|
Geometric mean titers (GMTs) of DENV-1 to 4 virus neutralization antibodies
Time Frame: 56 days
|
56 days
|
GMTs of DENV-1 to 4 virus neutralization antibodies
Time Frame: 84 days
|
84 days
|
Proportion of participants with viremia for each of DENV-1 to 4
Time Frame: 12 days
|
12 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: PRASAD KULKARNI, MD, SERUM INSTITUTE OF INDIA
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 17, 2019
Primary Completion (Actual)
June 11, 2021
Study Completion (Actual)
June 11, 2021
Study Registration Dates
First Submitted
July 25, 2019
First Submitted That Met QC Criteria
July 25, 2019
First Posted (Actual)
July 29, 2019
Study Record Updates
Last Update Posted (Actual)
January 3, 2024
Last Update Submitted That Met QC Criteria
December 29, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Dengusiil-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prevention of Dengue Fever
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseaseVietnam
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesPeru
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesMexico
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic FeverSingapore
-
Sanofi Pasteur, a Sanofi CompanyCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue DiseasesThailand
-
Sanofi Pasteur, a Sanofi CompanyUnited States Department of DefenseCompletedDengue | Dengue Fever | Dengue Hemorrhagic FeverUnited States
-
U.S. Army Medical Research and Development CommandGlaxoSmithKlineCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue Shock SyndromePuerto Rico
-
SanofiCompletedDengue Fever | Dengue Hemorrhagic Fever | Dengue VirusUnited States
-
SanofiCompletedDengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue VirusAustralia